Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine Renoprotective Effect in HBV-related Cirrhosis
NCT01693679Phase 4Unknown
- Start
- Sep 2012
- Primary completion
- Apr 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 4, open-label trial of telbivudine in hepatitis B (HBV) and Liver cirrhosis (LC) (4 arms). Primary endpoints: Glomerular Filtration Rate at 96 weeks and Serum Creatinine at 96 weeks. Status: unknown.
02
Drugs
telbivudine
03
Conditions
hepatitis B (HBV)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT01693679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01693679.